Please login to the form below

Not currently logged in
Email:
Password:

Johnson and Johnson’s second-in-command announces retirement plans

Sandra Peterson departs at the start of October

Sandra PetersonJohnson and Johnson is to say goodbye to its group worldwide chair Sandra Peterson, as the second-in-command leader will retire from her post from 1 October.

Peterson has held the role for six years, during which time she oversaw the company’s global operating infrastructure, implemented innovation and growth initiatives and supervised the consumer-facing businesses, the latter generating around £18bn in revenue for the company.

She was also tasked with getting that particular division back on track after J&J was plagued by a series of recalls, including 200,000 bottles of children’s cough drop medicine that was deployed in the US.

Peterson has also led J&J’s efforts in healthcare technology, leveraging design thinking to create solutions for patients, consumers and providers.

J&J says that after her departure, her responsibilities will be shared between Joaquin Duato, who has been leading the company’s pharmaceutical business and chief scientific officer Paul Stoffels.

Additional changes will see Jennifer Taubert succeed Duato, taking the helm of J&J’s global pharmaceutical business while Ashley McEvoy - who rejuvenated its eye-care business - will manage J&J’s group of medical device companies.

Finally, Kathy Wengel, who oversees the company’s manufacturing and Michael Sneed, chief communication officer, has been promoted to join J&J’s executive team, these moves taking place from 2 July.

Article by
Gemma Jones

25th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics